IPO - CG Oncology, Inc.

Form Type: S-3ASR

Filing Date: 2025-03-28

Corporate Action: Ipo

Type: New

Accession Number: 000119312525067207

Filing Summary: CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on bladder cancer treatment. The Company is developing cretostimogene grenadenorepvec (cretostimogene) as an alternative to Bacillus Calmette-Guérin (BCG) therapy for patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to BCG, a critical unmet need given the burdens of radical cystectomy. Anticipating possible FDA approval, CG Oncology is enhancing its commercial operations, including launch preparation and scientific communication activities. The registration statement includes two prospectuses: a base prospectus for securities offerings and a sales agreement prospectus for common stock up to $250 million under an Open Market Sale Agreement with Jefferies LLC. The common stock trades on the Nasdaq Global Select Market under the symbol 'CGON,' and the last reported sale price was $26.94 on March 27, 2025. Investors should consider the risks associated with investing in the Company's securities as emphasized in the 'Risk Factors' section of the prospectus.

Form Type: CORRESP

Filing Date: 2024-12-11

Corporate Action: Ipo

Type: New

Accession Number: 000119312524274852

Filing Summary: CG Oncology, Inc. has submitted a request to the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1 (File No. 333-283725). The company requests that the SEC declare the Registration Statement effective by 4:00 p.m. Eastern time on December 12, 2024, or as soon thereafter as possible. Legal counsel from Cooley LLP will assist in confirming the effective date over the phone. The company noted that a letter from the managing underwriters supporting the acceleration request will be sent under separate cover.